Wells Fargo last night downgraded Pliant Therapeutics (PLRX) to Equal Weight from Overweight with a price target of $4, down from $41. The ...

Pliant (PLRX) stock plunged 61% on news it has paused enrollment in a Phase 2b study of its drug bexotegrast in patients with ...

The widow of Wells Fargo HR, Willis Ayieko, recounted his tragic abduction and murder in October 2024. She said he was a ...

A new Hearts & Wallets survey shows financial advisory clients want proactivity, but too often are not getting it.

Proactivity, one of the top-growing "wants" of clients, also proved to be the biggest satisfaction gap. The report showed 45 percent of households nationally rate proactivity as highly important, but ...

A plan that will include razing the Phoenix Police Department’s longtime headquarters at Seventh Avenue and Washington Street and preparing the entire intersection for mixed-used development is moving ...

The company's press release indicated that the enrollment and dosing for the BEACON-IPF trial were voluntarily paused to review data and understand the DSMB's recommendation. While the study remains ...

At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All ...

Here's a look at 20 Greater Philadelphia development projects, some planned and others already underway, to keep an eye on ...

Pliant Therapeutics (NASDAQ:PLRX) experienced a significant adjustment in their stock price target as Needham analysts revised their expectations from $38.00 to $10.00. Despite the reduction, Needham ...

CFBP website on Thursday Three years ago, Wells Fargo was required to pay a total $3.7 billion to customers, including over ...